Scholars Central

Review articlePublished 22 Jul 2016

mTOR inhibitors in renal cell carcinoma

Authors: Chiara Battelli, Daniel C Cho

Clinical Practice

Volume 8 · Issue 4 · Pages 359

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The mammalian target of rapamycin (mTOR) is a downstream effector of the PI3-K/Akt/mTOR pathway. Allosteric inhibitors of mTOR, everolimus and temsirolimus, have shown promising clinical activity in advanced renal cell carcinoma but their effect is far from durable and only a subset of patients experience substantial benefit from these agents. The PI3-K/Akt/mTOR pathway represents an intricate network of fine regulation and feedback loops, and resistance to allosteric mTOR inhibitors may be embedded within this complexity. In this article we highlight the molecular elements of the PI3-K/Akt/mTOR pathway, the clinical experience with everolimus and temsirolimus in advanced renal cell carcinoma, and the future directions in terms of sequential therapy, combinational therapy and development of novel therapeutic agents.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Chiara Battelli”
  • BylineArticles whose byline prints “Daniel C Cho”